118 related articles for article (PubMed ID: 29389071)
1. Combinatorial Probes for High-Throughput Electrochemical Analysis of Circulating Nucleic Acids in Clinical Samples.
Das J; Ivanov I; Safaei TS; Sargent EH; Kelley SO
Angew Chem Int Ed Engl; 2018 Mar; 57(14):3711-3716. PubMed ID: 29389071
[TBL] [Abstract][Full Text] [Related]
2. Circulating cell-free DNA as a diagnostic and prognostic biomarker for non-small-cell lung cancer: a systematic review and meta-analysis.
Chen Z; Miao H; Zeng Q; Xu S; Chen Z; Liu K
Biomark Med; 2020 May; 14(7):587-597. PubMed ID: 31845833
[No Abstract] [Full Text] [Related]
3. Biosensors for liquid biopsy: circulating nucleic acids to diagnose and treat cancer.
Bellassai N; Spoto G
Anal Bioanal Chem; 2016 Oct; 408(26):7255-64. PubMed ID: 27497966
[TBL] [Abstract][Full Text] [Related]
4. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
[TBL] [Abstract][Full Text] [Related]
5. DNA Clutch Probes for Circulating Tumor DNA Analysis.
Das J; Ivanov I; Sargent EH; Kelley SO
J Am Chem Soc; 2016 Aug; 138(34):11009-16. PubMed ID: 27513828
[TBL] [Abstract][Full Text] [Related]
6. An electrochemical clamp assay for direct, rapid analysis of circulating nucleic acids in serum.
Das J; Ivanov I; Montermini L; Rak J; Sargent EH; Kelley SO
Nat Chem; 2015 Jul; 7(7):569-75. PubMed ID: 26100805
[TBL] [Abstract][Full Text] [Related]
7. High-Performance Nucleic Acid Sensors for Liquid Biopsy Applications.
Das J; Kelley SO
Angew Chem Int Ed Engl; 2020 Feb; 59(7):2554-2564. PubMed ID: 31332937
[TBL] [Abstract][Full Text] [Related]
8. Optimisation of an Electrochemical DNA Sensor for Measuring KRAS G12D and G13D Point Mutations in Different Tumour Types.
Attoye B; Baker MJ; Thomson F; Pou C; Corrigan DK
Biosensors (Basel); 2021 Feb; 11(2):. PubMed ID: 33562505
[TBL] [Abstract][Full Text] [Related]
9. Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping.
Guibert N; Tsukada H; Hwang DH; Chambers E; Cibas ES; Bale T; Supplee J; Ulrich B; Sholl LM; Paweletz CP; Oxnard GR
Lung Cancer; 2018 Aug; 122():72-75. PubMed ID: 30032849
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis of EGFR exon21 L858R point mutation as lung cancer biomarker by electrochemical DNA biosensor based on reduced graphene oxide /functionalized ordered mesoporous carbon/Ni-oxytetracycline metallopolymer nanoparticles modified pencil graphite electrode.
Shoja Y; Kermanpur A; Karimzadeh F
Biosens Bioelectron; 2018 Aug; 113():108-115. PubMed ID: 29753165
[TBL] [Abstract][Full Text] [Related]
11. [Research Advancement on EGFR Mutation Detection of Cell-free DNA and Tumor Cell in Peripheral Blood of Patients with Non-small Cell Lung Cancer].
Zhang Y; Xu Y; Wang M
Zhongguo Fei Ai Za Zhi; 2016 Nov; 19(11):766-772. PubMed ID: 27866520
[TBL] [Abstract][Full Text] [Related]
12. Use of SuperARMS EGFR Mutation Detection Kit to Detect EGFR in Plasma Cell-free DNA of Patients With Lung Adenocarcinoma.
Cui S; Ye L; Wang H; Chu T; Zhao Y; Gu A; Xiong L; Shi C; Jiang L
Clin Lung Cancer; 2018 May; 19(3):e313-e322. PubMed ID: 29329944
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumour DNA as a cancer biomarker.
Duffy MJ
Ann Clin Biochem; 2019 Jan; 56(1):42-48. PubMed ID: 30114930
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of the cobas EGFR Mutation Assay in Non-small-cell Lung Cancer Compared With Three Laboratory-developed Tests.
Nakamura H; Koizumi H; Sakai H; Kimura H; Miyazawa T; Marushima H; Saji H; Takagi M
Clin Lung Cancer; 2018 Mar; 19(2):170-174. PubMed ID: 29150249
[TBL] [Abstract][Full Text] [Related]
15. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
Ai B; Liu H; Huang Y; Peng P
Oncotarget; 2016 Jul; 7(28):44583-44595. PubMed ID: 27323821
[TBL] [Abstract][Full Text] [Related]
16. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
Malapelle U; Mayo de-Las-Casas C; Rocco D; Garzon M; Pisapia P; Jordana-Ariza N; Russo M; Sgariglia R; De Luca C; Pepe F; Martinez-Bueno A; Morales-Espinosa D; González-Cao M; Karachaliou N; Viteri Ramirez S; Bellevicine C; Molina-Vila MA; Rosell R; Troncone G
Br J Cancer; 2017 Mar; 116(6):802-810. PubMed ID: 28170370
[TBL] [Abstract][Full Text] [Related]
17. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumour DNA in
Cabanero M; Tsao MS
Curr Oncol; 2018 Jun; 25(Suppl 1):S38-S44. PubMed ID: 29910646
[TBL] [Abstract][Full Text] [Related]
19. Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.
Levy B; Hu ZI; Cordova KN; Close S; Lee K; Becker D
Oncologist; 2016 Sep; 21(9):1121-30. PubMed ID: 27388233
[TBL] [Abstract][Full Text] [Related]
20. Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma.
Rachiglio AM; Esposito Abate R; Sacco A; Pasquale R; Fenizia F; Lambiase M; Morabito A; Montanino A; Rocco G; Romano C; Nappi A; Iaffaioli RV; Tatangelo F; Botti G; Ciardiello F; Maiello MR; De Luca A; Normanno N
Oncotarget; 2016 Oct; 7(41):66595-66605. PubMed ID: 27448974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
